Skip to main content
EJNMMI Research
Fig. 2 | EJNMMI Research

Fig. 2

From: Kinetic analysis of dominant intraprostatic lesion of prostate cancer using quantitative dynamic [18F]DCFPyL-PET: comparison to [18F]fluorocholine-PET

Fig. 2

An iliac artery TAC (grey), the tumour TAC (light grey line with open circle marker, scaled up 4× to improve visibility) and the benign tissue TAC (light grey line with × marker, scaled up 4×) of a [18F]FCH patient (a) and a [18F]DCFPyL patient (b). Both patients had similar prostate cancer characteristics (PSA level 10.3 vs. 12.94 ng/mL; Gleason score 7 (3 + 4), the proportion of prostate involved with tumour 10%). The fitted curves (black) for both tracers using the F2TCM showed a strong correlation with measured TACs (R2 > 0.93). TAC, time-activity curve; FCH, fluorocholine; DCFPyL, 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid; PSA, prostate-specific antigen; F2TCM, flow-modified standard two-extravascular-tissue compartment model

Back to article page